Overview

SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors

Status:
Recruiting

Trial end date:
2021-09-01

Target enrollment:

Participant gender:

Summary

To determine the clinical benefit rate of selumetinib in combination with sirolimus in patients with unresectable or metastatic neurofibromatosis type 1 (NF1) associated or sporadic MPNST.

Phase:

Phase 2

Details

Lead Sponsor:

Sarcoma Alliance for Research through Collaboration

Collaborators:

AstraZeneca
United States Department of Defense

Treatments:

Everolimus
Sirolimus